Arcellx, Inc.

0 products tracked · names used in filings: Arcellx, Inc.

Upcoming milestones

Wed 23 Dec 2026🇺🇸 PDUFA datecompany-announcedin 39 days

anito-cel: PDUFA target action date (fourth-line relapsed/refractory multiple myeloma)

Arcellx, Inc. (ACLX); anitocabtagene autoleucel; BLA; status: set; "Food and Drug Administration with an anticipated Prescription Drug User Fee Act (PDUFA) action date of December 23, 2026."; filed 2026-02-23 · source

Recent milestones

No recent milestones.

Products

No products recorded.

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.